As Viking Therapeutics, Inc. (VKTX) approaches its first-quarter earnings report on April 29, 2026, the company faces severe financial pressures marked by a significant forecasted EPS decline of 151.27%. Despite these challenges, analysts from Raymond James and Piper Sandler maintain 'Strong Buy' ratings, buoyed by the firm's successful completion of patient enrollment in the Phase 3 VANQUISH-2 trial for its GLP-1 obesity treatment. The stark contrast between the company's low current stock price and optimistic analyst price targets, alongside ongoing cash flow issues, highlights the uncertainty surrounding VKTX's future.
“The most followed narrative for Viking Therapeutics points to a fair value of $92.72 per share compared with the last close at $35.20. The gap between price and narrative fair value is substantial and built on specific views about future obesity treatments and earnings power.”
“Smaller biotechs like Viking Therapeutics VKTX are also developing GLP-1-based therapies to challenge the incumbents. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity.”
“Given the mix of optimism around obesity treatments and concern about valuation and funding, this is a moment to move quickly and test the numbers yourself, then weigh the 1 key reward and 2 important warning signs.”
“Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026”
“Analyst sees GLP-1/GIP data readthrough as neutral-to-positive, with no meaningful LBM disadvantage and stronger weight loss profile supporting VKTX outlook.”
“Company has been rated SELL since 06/29/15. The Company's Fundamentals Look Very Poor Making an Investment in Its Shares Purely Speculative.”
“Average price target from 19 ratings: $93.59.”
“VKTX will report Q1 2026 earnings on 04/29/2026.”
“VKTX will report FY 2026 earnings on 02/10/2027.”
“Raymond James reiterated a Strong Buy rating and $118.00 price target on Viking Therapeutic (NASDAQ:VKTX).”
“Raymond James views the readthrough from this analysis as neutral to positive for Viking Therapeutic, noting it shows superior overall weight loss with a GLP-1/GIP and no obvious differentiation on lean body mass reduction in proportion to amount of weight lost between the drugs.”
“Viking Therapeutics has announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial, which evaluates the subcutaneous VK2735 in adults with obesity and type 2 diabetes.”